Pharmaceutical research institutions are increasing the usage of algorithmic models to screen patient candidates for Phase II and Phase III clinical trials. Regulatory bodies have begun requiring complete algorithmic auditing trails to prevent demographic bias in participant selection.
Validation Protocols
Data integrity protocols now require double-blind validation where synthetic control groups are utilized alongside real-world data. Industry compliance expenditures have risen 18% as biotech firms hire specialized auditing personnel to verify model transparency.